Advertisement
DHR vs RVTY
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Revvity, Inc. (RVTY) Stock Comparison
Key Takeaways
- Danaher (DHR) boasts a larger market capitalization of approximately $138 billion compared to Revvity's (RVTY) $10.4 billion, reflecting greater scale and diversification.
- DHR has delivered stronger year-to-date (YTD) performance at +14.4%, outpacing RVTY's +3.7% amid recent market activity.
- Both stocks operate in life sciences and diagnostics, but DHR shows higher return on equity (ROE, a measure of profitability relative to shareholders' equity) at 7.05% versus RVTY's 3.22%.
- Analyst price targets suggest similar upside potential around 30% for both, with DHR at $256 and RVTY around $110-115.
- Recent quarterly revenue growth edges higher for RVTY at 5.9% versus DHR's 4.6%, though DHR leads in EPS (earnings per share) growth at 10.2%.
Introduction
Danaher Corporation (DHR) and Revvity, Inc. (RVTY) are key players in the life sciences and diagnostics sectors, making them compelling comparables for investors eyeing healthcare innovation. This stock comparison analyzes their business models, recent performance, and market positioning to aid traders assessing relative strength in a volatile environment. Value-oriented investors may favor the larger, diversified DHR, while growth seekers might eye RVTY's focused niche amid shifting sentiment. Understanding these dynamics supports informed decisions on stock comparison and portfolio allocation in current market conditions.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a global conglomerate designing, manufacturing, and marketing products across biotechnology, life sciences, and diagnostics segments. Its portfolio includes mass spectrometers, flow cytometry tools, and clinical instruments under brands like Beckman Coulter and Leica Microsystems. In recent market activity, DHR shares have traded around $195, within a 52-week range of $180-$243, supported by a market cap exceeding $138 billion. The stock delivered robust YTD gains of 14.4%, reflecting resilience. Recent quarterly earnings showed a revenue shortfall but an EPS beat, alongside 4.6% year-over-year revenue growth and 10.2% EPS expansion. Sentiment remains positive with analysts maintaining outperform ratings and a $256 average price target, bolstered by strategic partnerships in infectious disease solutions and strong fundamentals like a 38.7 trailing price-to-earnings (P/E) ratio.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY), formerly PerkinElmer, delivers health sciences solutions including detection technologies, reagents, and software for genomics and diagnostics. Its offerings support genetic screening, infectious disease testing, and drug discovery under brands like EUROIMMUN and BioLegend. Shares have hovered near $93 in recent weeks, within a 52-week range of $81-$118, with a $10.4 billion market cap. YTD performance stands at 3.7%, trailing broader sector peers. Recent quarters featured 5.9% revenue growth and 3.9% EPS improvement, though valuation concerns and regulatory risks, particularly in China, temper enthusiasm. Analysts project a $110+ price target, implying upside, amid a 45.6 trailing P/E ratio, with mixed trading reflecting these dynamics.
Trending AI Robots
Tickeron's Trending AI Robots page features a curated selection of top-performing AI trading bots from its library of 351 bots that trade thousands of tickers across diverse strategies and timeframes. Only the most suitable for current market conditions—based on metrics like high annualized returns (ranging from +15% to +168%), win rates (54%-88%), and profit factors (1.5-11.7)—earn a spot among the 25 trending ones. These bots employ technical analysis, AI/ML models, and sector-specific approaches, such as swing trading industrials or scalping semiconductors like NVDA and SOXL, with average trade durations from 1 day to weeks and profit-to-drawdown ratios up to 22. Traders can explore these automated tools for varying risk appetites and market volatility. Visit Trending AI Robots to review performance stats and consider integrating them into strategies.
Head-to-Head Comparison
Danaher (DHR) and Revvity (RVTY) share life sciences exposure but differ in scale and focus: DHR's diversified segments provide stability, while RVTY emphasizes targeted diagnostics and genomics. Growth drivers include DHR's M&A (mergers and acquisitions) history and partnerships versus RVTY's reagent innovation. Recent momentum favors DHR with superior YTD returns and EPS growth, though RVTY edges revenue expansion. Risk factors weigh heavier on RVTY due to regulatory headwinds and higher P/E, contrasted by DHR's lower debt-to-equity (37.5% vs. 46.9%). Market sentiment tilts toward DHR for its ROE advantage and analyst conviction, positioning it for steadier relative performance.
Tickeron AI Verdict
Tickeron's AI analysis would currently favor DHR over RVTY, citing greater trend consistency, YTD momentum, diversified catalysts, and superior profitability metrics like ROE and EPS growth. While both offer analyst-backed upside, DHR's scale and stability enhance its relative positioning in recent market conditions, suggesting higher probability of outperformance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a StrongBuy and RVTY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while RVTY’s TA Score has 3 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 6 bearish.
- RVTY’s TA Score: 3 bullish, 6 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -2.28% price change this week, while RVTY (@Medical Specialties) price change was +1.31% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | RVTY | DHR / RVTY | |
| Capitalization | 127B | 11.1B | 1,144% |
| EBITDA | 7.08B | 773M | 916% |
| Gain YTD | -21.159 | 3.151 | -671% |
| P/E Ratio | 34.90 | 47.91 | 73% |
| Revenue | 24.8B | 2.9B | 855% |
| Total Cash | 5.7B | 860M | 663% |
| Total Debt | 18.5B | 3.35B | 552% |
DHR | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 81 | 89 | |
PRICE GROWTH RATING 1..100 | 58 | 49 | |
P/E GROWTH RATING 1..100 | 65 | 32 | |
SEASONALITY SCORE 1..100 | 26 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is in the same range as RVTY (15). This means that DHR’s stock grew similarly to RVTY’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RVTY (100). This means that DHR’s stock grew similarly to RVTY’s over the last 12 months.
DHR's SMR Rating (81) in the Medical Specialties industry is in the same range as RVTY (89). This means that DHR’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (49) in the Medical Specialties industry is in the same range as DHR (58). This means that RVTY’s stock grew similarly to DHR’s over the last 12 months.
RVTY's P/E Growth Rating (32) in the Medical Specialties industry is somewhat better than the same rating for DHR (65). This means that RVTY’s stock grew somewhat faster than DHR’s over the last 12 months.
| DHR | RVTY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 58% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 46% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 54% | 2 days ago 60% |
| Advances ODDS (%) | 10 days ago 54% | 5 days ago 66% |
| Declines ODDS (%) | 2 days ago 61% | 12 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 52% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.38% | ||
| TMO - DHR | 77% Closely correlated | -1.33% | ||
| A - DHR | 73% Closely correlated | +0.22% | ||
| RGEN - DHR | 68% Closely correlated | -2.06% | ||
| RVTY - DHR | 64% Loosely correlated | -1.83% | ||
| BIO - DHR | 64% Loosely correlated | -2.22% | ||
More | ||||